Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 - B. I. Rini, N. M. Tannir, B. Escudier, D. F. McDermott, M.-O. Grimm, C. Porta, T. Powles, C. K. Kollmannsberger, H. P. Gurney, S. S. Tykodi, M. Harrison, D. Y. C. Heng, V. Grünwald, T. K. Choueiri, S. Mekan - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Oxford University Press (OUP), Annals of Oncology, (29), p. viii309-viii310, 2018

DOI: 10.1093/annonc/mdy283.084

Links

Tools

Export citation

Search in Google Scholar

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

Journal article published in 2018 by B. I. Rini, N. M. Tannir, B. Escudier, D. F. McDermott, M.-O. Grimm, C. Porta, T. Powles, C. K. Kollmannsberger, H. P. Gurney, S. S. Tykodi, M. Harrison, D. Y. C. Heng, V. Grünwald, T. K. Choueiri, S. Mekan and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO